Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PUMP next week as thet are going to talk about a merger with European company
Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients
2020-11-30 08:36 ET - News Release
A significant percentage of COVID-19 recovery patients suffer from long-term diarrhea or other gastrointestinal disfunctions
Non-binding terms to fund activities in Europe
SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), announced today that Jaguar and Napo are planning to develop and commercialize crofelemer, the Company's novel proprietary drug, for an indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a ‘long-hauler' COVID-19 recovery patient population in Europe.
As part of this plan, the Company is engaged in preliminary discussions with Swiss Growth Forum, a sponsor of a European special purpose acquisition company, "Post Pandemic Recovery Equity" ("the SPAC"), regarding the SPAC's potential merger with an operational subsidiary of the Company to be established in Europe with an exclusive license to crofelemer and Mytesi® for the indications of inflammatory diarrhea and HIV-related diarrhea. The preliminary terms under discussion include an upfront cash license fee to Napo ranging from approximately $2.0 million to $10.0 million; funding for the European operation of at least $20 million to pursue clinical development of crofelemer for inflammatory diarrhea in a long-hauler COVID-19 recovery patient population; and equity ownership in the European subsidiary by Napo ranging from 30% to 49.9% post-acquisition by the SPAC, with lower equity ownership in conjunction with a higher up-front cash license fee received by Napo. Other customary financial terms include royalties and transfer pricing on the supply of crofelemer and Mytesi to the European operation.
Management of Jaguar is currently on a road show in Europe with Swiss Growth Forum seeking support for the anticipated European operation identified as a target for the Post Pandemic Recovery Equity SPAC, for which Swiss Growth Forum is a promoter.
The terms "long-hauler" and "chronic COVID" refer to COVID-19 survivors who suffer with symptoms which may include gastrointestinal distress (i.e. diarrhea, constipation, nausea, pain), fatigue, brain fog, forgetfulness, cardiovascular effects, and arthritis, for an extended period after recovery. It is theorized that these symptoms may result when the immune system in COVID-19 survivors continues to overreact even though the infection has passed. Long-hauler syndrome appears to be predominant in younger COVID-19 recovery patients and those who experienced a mild/asymptomatic case.
Inflammation in the GI track often manifests as diarrhea, and chronic diarrhea may be an observable symptom that can provide for early diagnosis of long-hauler syndrome. Early diagnosis of chronic COVID syndrome could help limit the burden of long-term chronic illness in COVID-19 recovery patients.
"Our focus on the new potential indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea for crofelemer is driven primarily by the emergence of the long-hauler COVID-19 recovery patients," Lisa Conte, Jaguar's president and CEO, commented. "Enteropathy, an inflammatory chronic syndrome typically affecting long-term HIV/AIDS survivors, brings on chronic diarrhea. We believe this situation is analogous to what we're seeing right now in COVID-19 recovery patients who are suffering from long-term diarrhea or other gastrointestinal disfunctions."
Endpoints being explored for possible clinical trials of crofelemer would include prophylaxis and/or symptomatic relief of diarrhea, reduction in inflammatory gut markers, gut biome restoration, and reduction in viral fecal shedding.
"Our exploratory discussions with Swiss Growth Forum in the European Post Pandemic Recovery Equity SPAC matches well to our intention to focus clinical exploration for this development project in Europe, where single-payer healthcare systems focus on preventative measures to diagnose and treat symptoms that can be a precursor to potentially chronic illness," Conte said. "It is estimated that up to 25% of people in the United Kingdom, for example, have already been infected with SARS-CoV-2, the virus that causes COVID-19, and it appears to be the general consensus that around 30% of COVID-19 patients end up suffering from long-hauler syndrome," added Conte. "With infection rates growing the way they are, we believe it's possible that 10% to 15% of the global population is at risk of experiencing long-hauler syndrome."
Napo has conducted intellectual property filings in support of the development of crofelemer for the potential indication of addressing inflammatory diarrhea, including specifically in a long-hauler post-COVID recovery situation. As with all potential follow-on indications, Napo prioritizes IP protection. Napo currently holds approximately 144 patents, the majority of which do not expire until 2027 - 2031, and approximately 39 patents pending.
Mytesi® (crofelemer) is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Mytesi is a non-opiate, plant-based, chloride ion channel modulating antidiarrheal medicine that is approved in the U.S. by the Food and Drug Administration (FDA) for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
The only oral plant-based prescription medicine approved under FDA Botanical Guidance, Mytesi is also in development for multiple possible follow-on indications, including cancer therapy-related diarrhea, a rare disease indication for adult patients with short bowel syndrome (SBS), supportive care for inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and idiopathic/functional diarrhea. As previously disclosed, Napo initiated its pivotal Phase 3 clinical trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy ("cancer therapy-related diarrhea" (CTD)) this past October. Crofelemer in pediatric liquid formulation is in development for a rare disease indication for infants and children with congenital diarrhea disorders (CDD) and pediatric SBS.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar and Napo plan to develop and commercialize crofelemer, the Company's novel proprietary drug, for an indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a long-hauler COVID-19 recovery patient population in Europe, the SPAC's potential merger with an operational subsidiary of the Company to be established in Europe with an exclusive license to crofelemer and Mytesi for the indications of inflammatory diarrhea and HIV-related diarrhea, the Company's belief that chronic diarrhea may be an observable symptom that can provide for early diagnosis of long-hauler syndrome, the Company's belief that early diagnosis of chronic COVID could help limit the burden of long-term chronic illness in COVID-19 recovery patients, the Company's expectations regarding possible endpoints for possible clinical trials of crofelemer in Europe, and development efforts related to other possible Mytesi or crofelemer follow-on indications. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/618735/Jaguar-Health-Announces-Plan-to-Develop-and-Commercialize-Crofelemer-the-Companys-Novel-Proprietary-Drug-for-the-Indication-of-Inflammatory-Diarrhea-Initially-in-Long-Hauler-COVID-19-Recovery-Patients
all out didn't break .60 plus didn't like the 720 million shares OS
Breaks 60 cents it's head to dollar land should be a very interesting day with huge volumes
SNDL Rumor About An Acquisition
If you rewind back to August 2020, Sundial Growers had announced it was initiating and continuing a process to explore strategic alternatives focused on maximizing shareholder value. And Sundial’s board of directors had authorized management and its external advisors to consider a broader range of strategic alternatives, including a potential sale of the company or a merger. AlternativeFinanceNews.com updated one of its articles saying that a press release is expected December 2 with a possible announcement about a Sundial merger.
https://pulse2.com/sndl-stock-price-increases-nasdaq-sundial-growers-32-86-why-it-happened/
SNDL Rumor About An Acquisition
If you rewind back to August 2020, Sundial Growers had announced it was initiating and continuing a process to explore strategic alternatives focused on maximizing shareholder value. And Sundial’s board of directors had authorized management and its external advisors to consider a broader range of strategic alternatives, including a potential sale of the company or a merger. AlternativeFinanceNews.com updated one of its articles saying that a press release is expected December 2 with a possible announcement about a Sundial merger.
https://pulse2.com/sndl-stock-price-increases-nasdaq-sundial-growers-32-86-why-it-happened/
AlternativeFinanceNews.com updated one of its articles saying that a press release is expected December 2 with a possible announcement about a Sundial merger.
Takeover or Merger ? SNDL Stock Price Increases 32.86%: Why It Happened
By Amit Chowdhry ? November 28, 2020
AlternativeFinanceNews.com updated one of its articles saying that a press release is expected December 2 with a possible announcement about a Sundial merger.
The stock price of Sundial Growers Inc (NASDAQ: SNDL) increased by 32.86% on Friday November 27 as it went from a previous close of $0.28 to $0.37 per share. These are some of the reasons why the stock price surged.
The stock price of Sundial Growers Inc (NASDAQ: SNDL) — a company that engages in the production, distribution, and sale of cannabis products — increased by 32.86% on Friday, November 27 as it went from a previous close of $0.28 to $0.37 per share. The company’s stock price also increased another 7.5% after hours to a price of $0.40 per share. SNDL also saw a bump in trading as 326 million shares were traded on Friday alone. These are some of the reasons why the stock price increased.
Rumor About An Acquisition
If you rewind back to August 2020, Sundial Growers had announced it was initiating and continuing a process to explore strategic alternatives focused on maximizing shareholder value. And Sundial’s board of directors had authorized management and its external advisors to consider a broader range of strategic alternatives, including a potential sale of the company or a merger. AlternativeFinanceNews.com updated one of its articles saying that a press release is expected December 2 with a possible announcement about a Sundial merger.
https://pulse2.com/sndl-stock-price-increases-nasdaq-sundial-growers-32-86-why-it-happened/
ROTFLMAO Disclosure: I/we have no positions in any stocks mentioned
Market disagrees the hit piece was on Nov 23 at 24 cents
Zach George, CEO of Sundial, will be participating in a panel discussion at 10:10 a.m. EST on December 2, 2020.
Yup you got that right its a hot market on the backs of Tesla
out 3/4's with 10k profit
HA you should of held instead of being a flipper $$$$$$$$$
Well NAKD was a 4 dollar stock last year so anybody's guess
keep a few long shares to see
20 cents easy today and could see .25 to 30 cents by close today
Year high was 4.00
50 cents to 1.00 should head back to
You can pay higher prices tomorrow
610,440,302 mil volume today so 20 cents plus tomorrow ?
EVER or EVGUF Golden Triangle High Grade Gold assays pending
Kevin Keough, Charlie Greig
Will the same management team have another winner like GTT
38 cents to 2.75 in a month
EVER she was a close associate with Bob Bishop (Gold Mining Stock Report) most likely the best NLW of all time and he still is working behind the scenes
Rosie Moore = Director (Independent) B.S. Geology, M.S. Geology, Kent State University. Ms. Moore has more than 35 years diverse international experience in the industry spanning a spectrum of roles from fieldwork and project management on prominent discoveries such as Voisey’s Bay, through mining analyst, corporate finance and portfolio management roles, to senior officer and director positions, including roles with Ivanhoe Capital, Yorkton Securities, Diamond Fields, Pan American Silver, Bear Creek and Geologic Resource Partners. Her work has involved multiple commodities and projects encompassing the range of development stages, in jurisdictions around the world.
Yup that really suks way to young
SMDZF or SMD check out the high grade coarse gold as well the same kind of coarse gold found in drill cores assays are coming very soon
scroll down
http://www.strategicmetalsltd.com/projects/mount-hinton
SMD SMDZF High grade gold assays pending should be hot stuff
Strategic Metals completes drilling at Mt. Hinton
2020-10-01 10:10 ET - News Release
Shares issued 96,980,967
SMD Close 2020-09-30 C$ 0.58
Mr. Douglas Eaton reports
STRATEGIC METALS COMPLETES DRILL PROGRAM AT ITS MT HINTON GOLD AND SILVER PROJECT, YUKON
Strategic Metals Ltd. has successfully concluded its 2020 drill program at its wholly owned Mt. Hinton gold/silver project. A total of 6,978 metres of diamond drilling was completed in 32 holes, all with HQ diameter core.
Mt. Hinton is a road-accessible project located in the Keno Hill district of the Tintina gold belt, in central Yukon. The property lies immediately southeast of silver/lead mines on Alexco Resources' Keno Hill property, which are expected to resume production before the end of the year, and 35 kilometres southeast of Victoria Gold's Eagle Mine, which was commissioned in June, 2020.
The drill program tested parts of three zones within a six km by 4.5 km area of known mineralization and gold-rich soil geochemistry. The targets in all three zones were vein complexes cutting a west-dipping stratigraphic section comprising thick quartzite beds interlayered with lesser phyllite horizons and gabbro sills. These are the same units that host the mineralized veins on the adjacent Keno Hill property.
The majority of the holes were drilled on a series of section lines across the Granite North zone where surface sampling returned numerous high assays, including a rock sample that graded 2,340 grams per tonne gold and a chip sample of 26.9 g/t over 1.2 m. The section lines cross a number of subparallel, five m to 25 m wide vein/breccia/alteration bands that were mapped in talus and outcrop within the up to 400 m wide zone. Collectively the section lines tested a 425 m strike length along the zone. All of the holes intersected abundant quartz veining of differing types. Many of the veins are limonite stained and contain vuggy cavities. Some veins host residual sulphide minerals, and native gold was observed in a few of them.
Five holes were drilled at the Southwest zone where a chip sample containing visible gold assayed 200 g/t gold over 1.2 m. All five holes intersected strong structures containing quartz veining. Some of the quartz veins host arsenopyrite but most are oxidized. The holes spanned a 330 m strike length along this 1,750 m long zone. On average the holes intersected the zone about 100 m down dip of surface.
Three holes targeted veins in the northern structural corridor. All three holes intersected mineralized veins but all were terminated for various reasons short of their ultimate target depth. The northern structural corridor is a 4 km long, up to 750 m wide zone that was the main focus of earlier work on the Mt. Hinton property. It contains numerous gold and silver rich veins, where historical chip samples assayed more than 10 g/t gold over widths of one m to 2.1 m.
Assay results of core samples from the drill holes have been severely delayed by overloading at the analytical laboratory. Problems related to COVID-19 safety protocols have been compounded by a rapid uptick in drill activity worldwide. Mt. Hinton core processing has been further delayed by the very rigorous sampling, sample preparation and analytical techniques being used to ensure that the results are as reliable as possible given the presence of coarse gold in some veins. To date, assay results are only available for one complete hole and two partial holes. These results are still subject to compilation and quality assurance/quality control review. Ideally, the first news release will be made in about two weeks and will comprise holes spanning the entire width of the first section line across the Granite North zone. A comprehensive section should provide a better idea of the distribution and character of the mineralization. The drilling and sampling programs are designed to evaluate potential for both bulk-tonnage and discrete vein targets.
Technical information in this news release has been approved by Matthew R. Dumala, PEng, a geological engineer with Archer, Cathro & Associates (1981) Ltd., and qualified person for the purpose of National Instrument 43-101.
About Strategic Metals Ltd.
Strategic is a project generator with a portfolio of more than 130 projects that are the product of over 50 years of focused exploration and research by a team with a record of major discoveries. Current projects include more than 80 properties where precious metals are a major component. Projects available for option, joint venture or sale include drill-confirmed prospects and drill-ready targets with high-grade surface showings, geochemical anomalies and geophysical features that resemble those at nearby deposits.
Strategic has a current cash position of over $9-million and large shareholdings in a number of active mineral exploration companies including 46.3 per cent of GGL Resources Corp., 36.3 per cent of Rockhaven Resources Ltd., 19.6 per cent of Precipitate Gold Corp., 18.7 per cent of Silver Range Resources Ltd. and 9.9 per cent of Trifecta Gold Ltd. Strategic also holds a 53.5-per-cent interest in Terra CO2 Technologies Holdings Inc., a private Delaware corporation that is developing an environmentally friendly, cost-effective alternative to Portland cement.
SASY brand new grass roots discovery Golden Triangle High Grade Gold
shares 29 million FD
Sassy drills visible gold in quartz at Westmore
2020-10-01 08:15 ET - News Release
Shares issued 29,082,961
SASY Close 2020-10-01 C$ 0.92
Mr. Mark Scott reports
QUARTZ VEIN SYSTEM SHOWS CONTINUITY TO DEPTH AT SASSY'S WESTMORE GOLD-SILVER TARGET
Vein sets recognized at surface at Sassy Resources Corp.'s Westmore gold target, including visible gold in quartz veins, have been intersected at depth in continuing first-ever drilling. Westmore is part of the company's 146-square-kilometre Foremore project in northwest British Columbia's prolific Eskay camp.
Over 800 chip, grab and composite samples have been collected since July over a mapped exposed surface area of 400 metres by 400 metres with initial assay results (see attached table) confirming high-grade gold values in samples where visible gold was observed and not observed.
Highlights
• The associated galena plus pyrite mineralization observed on surface at Westmore has been recognized in the quartz veins subsurface and to drill hole depths to 270 metres.
• Visible gold (VG) has been noted in the first two drill holes completed to date.
• Mineralized alteration zones consisting of abundant quartz veins having a stockwork-like appearance occur over drill hole widths of multiple metres.
• The extent of the alteration halo consisting of increased silicification and pyrite mineralization associated with the quartz veining has been impressive and for the most part was not seen on surface.
• The first two drill holes were completed from the same platform and drilled toward the south at dips of minus 45 degrees and minus 60 degrees (core lengths were 211 metres and 304.5 metres, respectively) to test sample numbers COO12623 and COO12624 (see attached table).
Additional drilling is planned to test the unknown depth extent of the Westmore system.
Mark Scott, Sassy president and chief executive officer, commented: "It is rare to have a grassroots target turn into an early-stage discovery like this after only a few months of fieldwork followed by the first two drill holes, but this speaks to the energy and boldness of our team and the prolific nature of this district. We will push the drilling as far into the fall as possible as we have multiple high-quality targets to test thanks to extensive mapping and sampling."
Surface sampling returns 157 grams per tonne Au in metallic check assay
Assay results are now being received for sampled quartz veins occurring 100 metres to 300 metres south of the original surface discovery reported Sept. 4, 2020.
Preliminary assay and check assay results at Westmore have highlighted widespread high-grade gold mineralization hosted within quartz veins occurring within the Westmore granodiorite intrusive and the overlying mafic volcanic (basalt) rocks. Sassy's approach to sampling the quartz veins has been to collect selective mineralized material from within the quartz veins at multiple sampling stations along the strike of the individual quartz veins. Where widths allow, chip samples have been collected perpendicular to the strike of the quartz veins. Samples collected typically weigh two to three kilograms. Sassy is currently in the process of verifying and checking numerous initial high-grade gold values with follow-up metallic assay processes.
SELECT WESTMORE COMPOSITE SAMPLES (REPRESENTATIVE VEIN MATERIAL)
Metallic
Fire assay (check assay)* Silver assay
Sample No. Sample description Au (g/t) Au (g/t) Ag (g/t)
COO12607 Quartz vein; VG, galena**, trace chalcopyrite, 175.5 157.0 44.0
100 m south of original discovery
COO12623 Quartz vein; VG, galena, trace pyrite, 270 m 16.1 54.4 14.2
south of original discovery
COO12511 Quartz vein; galena, minor pyrite, discovery vein 49.8 25.9 619.0
COO12507 Quartz vein; trace galena, pyrite, 300 m south 13.7 10.9 9.8
of original discovery
COO12624 Quartz vein; galena, trace pyrite, 300 m south 50.1 16.8 13.8
of original discovery
* Material for metallic check assays was collected at immediate vicinity of original sample location. Fire
assays are the original results.
** Observed disseminated-blebby galena in samples with sulphides 5 per cent or less.
Visible gold was noted in samples COO12607 and COO12623 and the observation of visible gold resulted in positive gold grades. Equally impressive is the amount of gold occurring in samples C0012507 and COO12511 in which no visible gold was noted and observed galena and pyrite mineralization was described as trace to minimal. This implies that fine, not visible, gold also occurs in quartz veins within the Westmore intrusive and overlying mafic volcanic rocks in substantial amounts.
Quality assurance/quality control
Sassy implemented an industry-standard QA/QC program for the field samples reported in this news release that included the insertion of blanks and standards. Samples were bagged in clear plastic bags together with prenumbered sample tags and remained on site until transportation to the lab. Samples were transported and submitted directly by company personnel to the MSALabs preparation facility at Terrace, B.C., for gold and multielement analysis. Samples were crushed to 70 per cent passing two millimetres, split to 250 grams and pulverized to a pulp with 85 per cent passing 75 micrometres. The pulps were then shipped to MSALabs laboratory in Langley, B.C., where they were all analyzed for 48 elements by multielement ICP-AES/IMS under four-acid digestion and 50-gram fusion fire assay with atomic absorption finish. Samples that reported Au values over 10 g/t were reanalyzed by the gravimetric method, and those with Ag values over 100 ppm were reanalyzed by ICP-AES ore grade methods. In addition, Sassy has requested MSALABS to perform multiple check assays on coarse reject material utilizing a 500-gram split and to perform metallic screening analyses on all gold results over 10.0 g/t Au. MSALabs is an accredited lab independent of Sassy Resources.
As part of Sassy QA/QC protocol, check assays of MSALabs results were performed at Actlabs laboratory in Kamloops, B.C. Within the group of samples selected for check assay, Sassy inserted several blanks and standards. Samples were crushed up to 80 per cent passing two millimetres, a riffle split of 500 g was further pulverized to 98 per cent passing 105 micrometres. Pulps were analyzed for Au by fire assay (50 g) with an atomic absorption finish. All fire assays exceeding 10 g/t Au were assayed by metallic screen (500 g) sieved at 100 mesh (149 micrometres) with assays performed on the entire over 100 mesh and two splits of the minus 100 mesh fraction. A final assay is calculated based on the weight of each fraction. In addition, a 58-element plus S, multielement, four-acid near total digestion assay was performed by ICP-MS. Overlimit analyses were performed for Ag by four-acid ICP-OES technique. Actlabs is an accredited lab independent of Sassy Resources.
Qualified person
The technical information in this news release has been reviewed and approved by Ian Fraser, PGeo, vice-president of exploration for Sassy Resources. Mr. Fraser is the qualified person responsible for the scientific and technical information contained herein under National Instrument 43-101 standards.
About Sassy Resources Corp.
Sassy Resources is an exploration-stage resource company currently engaged in the identification, acquisition and exploration of high-grade precious metal and base metal projects in North America. Its current focus is on the Foremore gold-silver project located in the Eskay camp, Liard mining division, in the heart of northwest British Columbia's prolific Golden Triangle.
We seek Safe Harbor.
PDM report pegs at 60 cents with 1 million oz's Palladium
6 fold Discovery now = 3.60 per share ?
But there is clearly a lot more than 1 million ounces of palladium equivalent at LK. An additional million ounces could make this a C$0.60 stock.https://bluelakesadvisors.com/palladium-one-a-noble-metals-story-to-note/
NKORF PDM Palladium One rises on 'major discovery' in Finland
Palladium One Mining shares surged yesterday as the explorer announced “a major discovery” at its LK project in Finland.
https://www.mining-journal.com/discovery/news/1396146/palladium-one-rises-on-major-discovery-in-finland
PDM major discovery Drill maps core photos
https://www.newsfilecorp.com/release/63775
plus they have 1.1 mil oz's palladium already about 3 billion in value
increased 6 fold with new major discovery
Eric Sprott owns 20% of company
better to buy here at these prices today
Kartoon Channel! Launches on Samsung Smart TVs, Sending Genius Brands Stock Soaring
The increased distribution should lead to future ad-revenue growth.
https://www.fool.com/investing/2020/09/25/kartoon-channel-launches-on-samsung-smart-tvs-send/
INOTD PAI Makel Approval is coming with Official Launch announced in Video
COVID19 Rapid Test Kit BLRZF 0r BLR Signed Deal with Multi National Company in Taiwan Medigen Biotechnology Corp. + TBG Biotechnology Corp.
https://www.blackhawkgrowth.com/medigen-biotech/
https://www.blackhawkgrowth.com/wp-content/uploads/2020/09/FILE_2099.pdf
today 3.5 cents
AISSF or AIS Next door to Fosterville High Grade Gold Mine in Aussie Land
KL stock from 3 buks to over 70 today on this high grade gold find
FSX and NBR also there
AIS watch for another land deal coming
BLRZF or BLR .025 cents covid Rapid Test Kits
SNANF or Sona was a 15,000 percent gainer
BLRZF or BLR expecting sales deal next week
https://www.blackhawkgrowth.com/2020/09/blackhawk-provides-corporate-update/
Sales and distribution of the test kits has commenced. Negotiations have begun with a First Nations group in California and the Corporation’s sales teams have been approached by several private sector groups and laboratories that have expressed interest in large purchase orders.
NAKD Bottom looks like its in from 7 buks to .143 cents
NAKD Bottom looks like its in from 7 buks to .143 cents
i'll check it out Thanks